LEADER 04443nam  22014893a 450 
001 9910346841803321
005 20250203235437.0
010   $a9783038429500
010   $a3038429503
024 8 $a10.3390/books978-3-03842-950-0
035   $a(CKB)4920000000095222
035   $a(oapen)https://directory.doabooks.org/handle/20.500.12854/51985
035   $a(ScCtBLL)12fc4049-75dc-4b98-becb-675f4496a857
035   $a(OCoLC)1163819274
035   $a(oapen)doab51985
035   $a(EXLCZ)994920000000095222
100   $a20250203i20182019  uu 
101 0 $aeng
135   $aurmn|---annan
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 00$aLooking Forward To The Future of Heparin : $eNew Sources, Developments and Applications /$fGiangiacomo Torri, Jawed Fareed
210   $cMDPI - Multidisciplinary Digital Publishing Institute$d2018
210  1$aBasel, Switzerland :$cMDPI,$d2018.
215   $a1 electronic resource (282 p.)
311 08$a9783038429494 
311 08$a303842949X 
330   $aLooking Forward to the Future of Heparin: New Sources, Developments and Applications
606   $aChemistry$2bicssc
610   $aalginate
610   $aedema
610   $aHeparin Red
610   $asolid lipid nanoparticles
610   $aFe3O4·DA-BSA/HA
610   $adermatan sulfate
610   $asulfated alginate
610   $aporcine heparin
610   $atheranostics
610   $alow-molecular-weight heparin
610   $aArixtra®
610   $abiomaterials
610   $ahepcidin
610   $aovarian cancer
610   $airon oxide nanoparticles
610   $aheparin-induced thrombocytopenia
610   $abone morphogenetic protein (BMP)
610   $ahyaluronic acid (HA)
610   $acrude heparin
610   $aplatelets
610   $aresistance
610   $asclerostin
610   $aLMWH
610   $agremlin
610   $alow molecular weight heparin (LMWH)
610   $alow molecular weight glycosaminoglycans
610   $ahuman plasma
610   $asingle crystal X-ray structure
610   $airon homeostasis
610   $anoggin
610   $asuper paramagnetic iron oxide nanoparticles (SPION)
610   $amanufacturing methods
610   $apaclitaxel (PTX)
610   $abrain injury
610   $abovine heparin
610   $ainflammation
610   $aqNMR
610   $aantithrombin
610   $areference standard
610   $aquantitative NMR
610   $aenoxaparin
610   $adanaparoid sodium
610   $aNMR
610   $aGDNF
610   $aorthogonal multi-analytical methods
610   $aternary complex
610   $aheparan sulphate
610   $aserglycin
610   $abovine serum albumin (BSA)
610   $aHSQC
610   $arecombinant expression
610   $aheparin
610   $aheparin oligosaccharides
610   $afunctional assay
610   $aBMP antagonists
610   $aintestinal lymphatic absorption
610   $asize exclusion chromatography
610   $aheparin coating
610   $adiagnosis
610   $abioreactor
610   $aanemia
610   $aproteoglycan
610   $aheparin process
610   $aPCA
610   $achemometric
610   $afluorescent probe
610   $apharmacopeia
610   $aaffinity chromatography
610   $acomponent quantitative analysis
610   $aFondaparinux sodium
610   $aperylene diimide dyes
610   $athrombin inhibition
610   $aextended physicochemical characterization
610   $acisplatin
610   $aglycosaminoglycans
610   $aTGF-?
610   $achondroitin sulfate
610   $adalteparin
610   $asequence and compositional investigations
610   $amolecular weight
610   $amagnetic resonance imaging (MRI)
610   $aindustrial
610   $aLC-MS
610   $aiduronic acid conformation
610   $aheparan sulfate
610   $agrowth and differentiation factor (GDF)
610   $aassay
610   $asubarachnoid hemorrhage
615  7$aChemistry
700   $aTorri$b Giangiacomo$01296739
702   $aFareed$b Jawed
801  0$bScCtBLL
801  1$bScCtBLL
906   $aBOOK
912   $a9910346841803321
996   $aLooking Forward To The Future of Heparin$94318166
997   $aUNINA